#EB003
EB003 represents a promising step toward the next generation of precision antimicrobials for combating STEC infections and potentially other bacterial pathogens!
March 4, 2025 at 12:31 PM
More importantly, in an infant rabbit disease model, EB003 mitigated clinical symptoms and accelerated epithelial repair at therapeutically relevant doses.
March 4, 2025 at 12:31 PM
We could further show that EB003 can drastically reduce bacterial burden in mouse colonization model.
March 4, 2025 at 12:31 PM
Critically, EB003 kills target bacteria with no detectable toxin release.
March 4, 2025 at 12:31 PM
EB003 uses a Cas12 nuclease to cleave >99% of all Shiga toxin (stx) variants found in O157 strains, leading to bacterial killing and suppression of toxin production.
March 4, 2025 at 12:31 PM
We developed EB003, a non-replicative CRISPR-based antimicrobial that selectively targets and eliminates O157 STEC clinical isolates while preventing toxin release.
March 4, 2025 at 12:31 PM
January 3, 2026 at 10:09 AM
“Sector” Estella Boersma — EB003 (2025)
January 26, 2026 at 7:49 AM